Navigation Links
Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
Date:11/19/2008

RICHMOND, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in the research and development of novel zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification, announced today the appointment of Paul B. Cleveland, executive vice president, corporate development and chief financial officer of Affymax, Inc., to its board of directors, effective November 19, 2008. Mr. Cleveland will also serve as chair of Sangamo's audit committee.

"We are very pleased to welcome Paul to Sangamo's board," stated Edward Lanphier, Sangamo's president and CEO. "His significant experience and success in biotechnology industry finance and business development will aid us in all aspects of our company's operations, including clinical and commercial development of our ZFP Therapeutic(TM) programs."

Mr. Cleveland has served as executive vice president, corporate development and chief financial officer of Affymax, Inc. since January 2006. In such capacity, he has responsibility for all business development, strategic planning, finance, investor relations and legal functions. He negotiated a worldwide collaboration with Takeda that was honored with the "Allicense 2007 Breakthrough Alliance Award" at the Recombinant Capital Allicense conference. Mr. Cleveland also led preparations for and execution of Affymax's initial public offering of common stock which was characterized as "the strongest biotech offering of 2006" by Business Week. Together these transactions added more than $230 million to Affymax's cash balance in one year.

From 2004 to 2006, Mr. Cleveland served as a managing director at Integrated Finance, Ltd., an investment bank, and from 1996 to 2003 as a managing director and head of west coast mergers and acquisitions at J.P. Morgan Chase and Co. (
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
2. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
3. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
4. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
5. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
6. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
7. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
8. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
9. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
10. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
11. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
(Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... 2014 Terascala, the industry leader in ... Swahn, a former vice president of product management for ... president of marketing. Terascala’s software when combined with leading ... the highest performance and most reliable solutions for processing ... Terascala’s channel expansion and broaden its product portfolio. His ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... 11 , - TB-402 Shows Clear Promise ... Thromboembolic Disorders., ThromboGenics NV (Euronext Brussels:THR), a ... that the results of the,first Phase I trial ... Society of Hematology (ASH) 49th Annual Meeting in ...
... The Perrigo Company,(Nasdaq: PRGO ; TASE) announced today ... final approval to Dexcel Pharma,Technologies, Ltd. for 20 mg ... this product for the store brand,over-the-counter (OTC) market in ... during the first quarter of calendar year 2008,with full ...
... Tutogen Medical, Inc.,(Amex: TTG ), a leading manufacturer of ... tissue, today announced,financial results for the fiscal year and fourth ... Highlights for the fiscal year include:, -- Total ... of dental products increased 38% in fiscal year 2007; ...
Cached Biology Technology:ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 3ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 4Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole; Raises Full Year Earnings Guidance 2Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole; Raises Full Year Earnings Guidance 3Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 2Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 3Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 4Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 5Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 6Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 7Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 8Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 9Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 10
(Date:7/11/2014)... 2014 Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/11/2014)... the hippocampus, the marginal division of the striatum ... is the impact degree of substance P in ... function? Yan Yu and his team, College of ... immunofluorescence staining, that substance P receptor, neurokinin 1 ... marginal division of normal rats. Unilateral or bilateral ...
(Date:7/11/2014)... Research and Markets has announced ... - Industry Analysis Size Share Growth Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 The rising ... need for high level security in both private and ... as username and passwords, tokens etc. are vulnerable to ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... A UC Riverside-led research team has found that as ... they do so by increasing only that segment of ... of an individual to contribute offspring to the next ... have studied for long, the researchers found that guppies ...
... to treat diseases such as cystic fibrosis, reduce bacterial ... and the University of Texas at Austin has determined ... be pivotal in preventing certain bacterial infections in plants, ... the Proceedings of the National Academy of Sciences. ...
... the prevailing belief that adult brain cells don't grow, a ... in the Dec. 27 issue of Public Library of Science ... occur in mature brains. , This finding means that ... to replace ones damaged by disease or spinal cord injury, ...
Cached Biology News:Fish evolve a longer lifespan by evolving a longer reproductive period, researchers find 2Scientists determine structure of enzyme that disrupts bacterial virulence 2MIT researcher finds neuron growth in adult brain 2MIT researcher finds neuron growth in adult brain 3
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... The Jouan B4i ventilated and BR4i refrigerated ... and low speed operation at a low sound ... accessories certified for biocontainment. Their AUTO-LOCK rotor exchange ... is ready for use within seconds. ...
Sterile, individually wrapped, 4mm Cuvettes...
... fully flexible quadrupole MS detector optimized for ... 1-D and 2-D LC, as well as ... a drying gas system to create a ... for low-to-medium polarity compounds, while providing for ...
Biology Products: